Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis13 Dec 2007
Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma13 Dec 2007
Grant of Warrants in Genmab A/S13 Dec 2007
Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic11 Dec 2007
Genmab's HuMax-CD38 Enters Phase I/II Clinical Trial for Multiple Myeloma7 Dec 2007
Genmab Wins Scrip's Biotech Company of the Year Award5 Dec 2007
Genmab's Total Number of Voting Rights and Total Share Capital30 Nov 2007
Genmab Announces Update on Recruitment of Patients in Ofatumumab CLL Pivotal Study
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
28 Nov 2007
Articles of Association of Genmab A/S dated November 21, 200726 Nov 2007
Capital Increase in Genmab as a Result of Employee Warrant Exercise21 Nov 2007
Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program20 Nov 2007
Report Pursuant to Section 28a of the Danish Securities Trading Act20 Nov 2007
  • Previous
  • 1
  • More pages
  • 115
  • 116
  • 117
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863